NCT01711294

Brief Summary

To document impact of EUS-FNA needle size and flexibility on effectiveness of pancreatic cystic lesions (PCL) aspiration, on ability to obtain sufficient material for standard diagnostic testing, and on diagnostic accuracy of EUS-FNA aspirate for differentiation of mucinous (pre-malignant) and non-mucinous cysts.

Trial Health

90
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
250

participants targeted

Target at P75+ for not_applicable

Timeline
Completed

Started Jan 2013

Longer than P75 for not_applicable

Geographic Reach
3 countries

8 active sites

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

September 26, 2012

Completed
26 days until next milestone

First Posted

Study publicly available on registry

October 22, 2012

Completed
3 months until next milestone

Study Start

First participant enrolled

January 8, 2013

Completed
4.4 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

June 6, 2017

Completed
2.5 years until next milestone

Study Completion

Last participant's last visit for all outcomes

December 18, 2019

Completed
11 months until next milestone

Results Posted

Study results publicly available

November 12, 2020

Completed
Last Updated

January 15, 2021

Status Verified

January 1, 2021

Enrollment Period

4.4 years

First QC Date

September 26, 2012

Results QC Date

October 20, 2020

Last Update Submit

January 14, 2021

Conditions

Keywords

Pancreatic Cystic LesionsPCLEUS-FNA

Outcome Measures

Primary Outcomes (1)

  • Volume of Aspirated Cyst Fluid as a Function of Estimated Maximal Volume

    Volume of aspirated cyst fluid as a function of estimated maximal volume, based on pre-aspiration EUS measure of cyst diameter (s) (% aspiration of total estimated volume)

    At procedure (Up to 1 hour)

Secondary Outcomes (15)

  • Number of Patients With Related Adverse Events

    30 days

  • Change in Volume of Cyst Post Initial Procedure Compared to Pre Procedure

    Procedure (Up to 1 hour)

  • Number of Participants With Successful Echoendoscopic Fine Needle Aspiration of PCL

    Procedure (up to 1 hour)

  • Number of Participants With PCL Reached/Penetrated

    Procedure (Up to 1 hour)

  • Number of EUS-FNA Needle Passes at Initial Procedure.

    Procedure (Up to 1 hour)

  • +10 more secondary outcomes

Study Arms (3)

19 G Flex Needle

ACTIVE COMPARATOR

Device: Expect™ Endoscopic Ultrasound Aspiration Needle (19 G Flex)

Device: 19 G Flex Needle

22 G Needle

ACTIVE COMPARATOR

Device: Expect™ Endoscopic Ultrasound Aspiration Needle (22 G)

Device: 22 G Needle

19 G Needle

ACTIVE COMPARATOR

Device: Expect™ Endoscopic Ultrasound Aspiration Needle (19 G)

Device: 19 G Needle

Interventions

Fine Needle Aspiration of PCL with a 19 G Flex needle. If unsuccessful, a salvage procedure will be done with 19 G or 22 G needle.

19 G Flex Needle

Fine Needle Aspiration of PCL with a 22 G needle. If unsuccessful, a salvage procedure will be done with 19 G Flex needle.

22 G Needle

Fine Needle Aspiration of PCL with a 19 G needle. If unsuccessful, a salvage procedure will be done with 19 G Flex needle.

19 G Needle

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Pancreatic cystic lesion measuring 13mm or greater in largest diameter.
  • Indicated for EUS evaluation of the PCL including EUS-FNA.
  • Age 18 years of age or older.
  • Willing and able to comply with the study procedures and provide written informed consent form to participate in the study.

You may not qualify if:

  • Cysts in which FNA is not indicated based on review by the clinician, including potential concern of blood vessel location relative to the cyst.
  • Requirement for anticoagulation using clopidogril, warfarin, or other long acting antiplatelet agents (with the exception of aspirin) that cannot be safely stopped according to institutional guidelines.
  • Standard contraindications for EUS.
  • Known pancreatic pseudocyst.
  • Pregnancy.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (8)

Mayo Clinic

Scottsdale, Arizona, 85259, United States

Location

Mayo Clinic

Jacksonville, Florida, 32224, United States

Location

Indiana University Medical Center

Indianapolis, Indiana, 46202, United States

Location

Massachusetts General Hospital

Boston, Massachusetts, 02114, United States

Location

Beth Israel Deaconess Medical Center

Boston, Massachusetts, 02215, United States

Location

New York Presbyterian Hospital/Columbia University Medical Center

New York, New York, 10032, United States

Location

Changhai Hospital

Shanghai, 200433, China

Location

Asian Institute of Gastroenterology

Hyderabad, 500 082, India

Location

Related Publications (1)

  • Al-Haddad M, Wallace MB, Brugge W, Lakhtakia S, Li ZS, Sethi A, Pleskow D, Nguyen CC, Pannala R, DeWitt J, Raimondo M, Woodward TA, Ramchandani MJ, Jin Z, Xu C, Faigel DO. Fine-needle aspiration of pancreatic cystic lesions: a randomized study with long-term follow-up comparing standard and flexible needles. Endoscopy. 2021 Nov;53(11):1132-1140. doi: 10.1055/a-1311-9927. Epub 2021 Feb 4.

MeSH Terms

Interventions

Needles

Intervention Hierarchy (Ancestors)

Equipment and Supplies

Results Point of Contact

Title
Lina Ginnetti, Clinical Endoscopy Director
Organization
Boston Scientific Corporation

Study Officials

  • Michael B Wallace, MD,MPH

    Mayo Clinic

    PRINCIPAL INVESTIGATOR

Publication Agreements

PI is Sponsor Employee
No
Restriction Type
GT60
Restrictive Agreement
Yes

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
NONE
Purpose
DIAGNOSTIC
Intervention Model
PARALLEL
Sponsor Type
INDUSTRY
Responsible Party
SPONSOR

Study Record Dates

First Submitted

September 26, 2012

First Posted

October 22, 2012

Study Start

January 8, 2013

Primary Completion

June 6, 2017

Study Completion

December 18, 2019

Last Updated

January 15, 2021

Results First Posted

November 12, 2020

Record last verified: 2021-01

Locations